CO5180582A1 - Soluciones farmaceuticas de levosimendan - Google Patents

Soluciones farmaceuticas de levosimendan

Info

Publication number
CO5180582A1
CO5180582A1 CO00067212A CO00067212A CO5180582A1 CO 5180582 A1 CO5180582 A1 CO 5180582A1 CO 00067212 A CO00067212 A CO 00067212A CO 00067212 A CO00067212 A CO 00067212A CO 5180582 A1 CO5180582 A1 CO 5180582A1
Authority
CO
Colombia
Prior art keywords
levosimendan
pharmaceutical solutions
less
solution
salt
Prior art date
Application number
CO00067212A
Other languages
English (en)
Inventor
Reijo Backstrom
Paivi Granvik
Ritva Haikala
Sirpa Pelttari
Eva Saukko
Reija Yrjola
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8555263&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5180582(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orion Corp filed Critical Orion Corp
Publication of CO5180582A1 publication Critical patent/CO5180582A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una solución acuosa farmacéutica que comprende levosimendan o una o una sal de este como un ingrediente activo el valor de pH de la solución es inferior de 5, preferiblemente aproximadamente 4,5 o inferior, y opcionalmente un agente de mejoramiento de la solubilidad.
CO00067212A 1999-09-10 2000-09-06 Soluciones farmaceuticas de levosimendan CO5180582A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI991925A FI109659B (fi) 1999-09-10 1999-09-10 Levosimendaanin farmaseuttisia liuoksia

Publications (1)

Publication Number Publication Date
CO5180582A1 true CO5180582A1 (es) 2002-07-30

Family

ID=8555263

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00067212A CO5180582A1 (es) 1999-09-10 2000-09-06 Soluciones farmaceuticas de levosimendan

Country Status (39)

Country Link
US (2) US6730673B1 (es)
EP (1) EP1210085B1 (es)
JP (1) JP4708648B2 (es)
KR (1) KR100869752B1 (es)
CN (1) CN1203855C (es)
AR (1) AR025449A1 (es)
AT (1) ATE315937T1 (es)
AU (1) AU771027B2 (es)
BG (1) BG65827B1 (es)
BR (1) BRPI0013924B8 (es)
CA (1) CA2382013C (es)
CO (1) CO5180582A1 (es)
CZ (1) CZ303095B6 (es)
DE (1) DE60025627T2 (es)
DK (1) DK1210085T3 (es)
EA (1) EA005067B1 (es)
EE (1) EE05375B1 (es)
ES (1) ES2256034T3 (es)
FI (1) FI109659B (es)
HK (1) HK1049282B (es)
HR (1) HRP20020298B1 (es)
HU (1) HU228340B1 (es)
IL (2) IL148379A0 (es)
IS (1) IS2244B (es)
ME (1) ME00523B (es)
MX (1) MXPA02002423A (es)
MY (1) MY125984A (es)
NO (1) NO331989B1 (es)
NZ (1) NZ517605A (es)
PL (1) PL202356B1 (es)
PT (1) PT1210085E (es)
RS (1) RS50445B (es)
SI (1) SI1210085T1 (es)
SK (1) SK287154B6 (es)
TR (1) TR200200620T2 (es)
TW (1) TWI242434B (es)
UA (1) UA73954C2 (es)
WO (1) WO2001019334A2 (es)
ZA (1) ZA200201828B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI109659B (fi) * 1999-09-10 2002-09-30 Orion Yhtymae Oyj Levosimendaanin farmaseuttisia liuoksia
FI20010233A0 (fi) * 2001-02-08 2001-02-08 Orion Corp Menetelmä sydämen vajaatoiminnan hoitoon
CN100428937C (zh) * 2003-10-30 2008-10-29 北京海合天科技开发有限公司 左西孟旦冷冻干燥组合物
CN100367964C (zh) * 2004-04-29 2008-02-13 王思清 左西孟旦-β环糊精包含物制剂
WO2006087419A2 (en) * 2005-02-18 2006-08-24 Orion Corporation A method for administering levosimendan
WO2008082871A1 (en) * 2006-12-28 2008-07-10 Orion Corporation Formulations of levosimendan for parenteral administration
WO2012093404A2 (en) 2011-01-03 2012-07-12 Gufic Biosciences Limited Parenteral formulations of levosimendan
US9597425B2 (en) * 2011-10-18 2017-03-21 St. Teresa Medical, Inc. Method of forming a hemostatic product
AU2013262438B2 (en) * 2012-05-18 2017-03-16 Luoda Pharma Limited Liquid formulation
CN105106113B (zh) * 2015-09-30 2019-07-26 济南康和医药科技有限公司 一种左西孟旦注射液及其制备方法
ES2782106T3 (es) * 2015-11-06 2020-09-10 Carinopharm Gmbh Formulaciones mejoradas de levosimendán para administración intravenosa como infusión o inyección y como concentrado de infusión
US10828387B2 (en) 2015-11-12 2020-11-10 St. Teresa Medical, Inc. Method of sealing a durotomy
CN108261398A (zh) * 2016-12-30 2018-07-10 齐鲁制药有限公司 一种含有左西孟旦的供注射用药物制剂及其制备方法
US10953128B2 (en) 2017-11-02 2021-03-23 St. Teresa Medical, Inc. Fibrin sealant products
CN111474289A (zh) * 2019-10-31 2020-07-31 武汉嘉诺康医药技术有限公司 一种利用反相色谱分离分析左西孟旦中右西孟旦的方法
AU2020408323A1 (en) 2019-12-16 2022-08-11 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HF-pEF)
CN111514147B (zh) * 2020-05-12 2021-09-17 成都欣捷高新技术开发股份有限公司 用于急性失代偿心力衰竭症状的左西孟旦钠药用组合物及制备方法
US11760730B2 (en) * 2021-01-11 2023-09-19 Navinta, Llc Process for the preparation of high purity Levosimendan
WO2023027670A2 (en) * 2021-08-23 2023-03-02 Tum Ekip Ilac Anonim Sirketi Lyophilized levosimendan compositions
CN115518037A (zh) * 2022-10-14 2022-12-27 上药东英（江苏）药业有限公司 一种安全质量稳定的左西孟旦注射剂组合物及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2251615B (en) 1991-01-03 1995-02-08 Orion Yhtymae Oy (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile
GB2266841A (en) 1992-05-06 1993-11-17 Orion Yhtymae Oy Compounds for use as anti-ischemic medicaments
GB9606474D0 (en) 1996-03-27 1996-06-05 Orion Yhytmo Oy Method for obtaining pure enantiomers of a pyridazinone derivative
GB9614098D0 (en) * 1996-07-05 1996-09-04 Orion Yhtymae Oy Transdermal delivery of levosimendan
FI980902A (fi) * 1998-04-23 1999-10-24 Orion Yhtymae Oyj Levosimendaanin stabiileja koostumuksia
FI109659B (fi) * 1999-09-10 2002-09-30 Orion Yhtymae Oyj Levosimendaanin farmaseuttisia liuoksia

Also Published As

Publication number Publication date
CA2382013A1 (en) 2001-03-22
EA005067B1 (ru) 2004-10-28
PT1210085E (pt) 2006-05-31
PL202356B1 (pl) 2009-06-30
SK3272002A3 (en) 2002-12-03
JP4708648B2 (ja) 2011-06-22
CZ303095B6 (cs) 2012-03-28
BRPI0013924B8 (pt) 2021-05-25
NO20021090L (no) 2002-03-05
YU16902A (sh) 2004-09-03
EE05375B1 (et) 2011-02-15
IS6296A (is) 2002-03-06
CN1373665A (zh) 2002-10-09
CA2382013C (en) 2009-08-11
SI1210085T1 (sl) 2006-04-30
NO331989B1 (no) 2012-05-21
WO2001019334A3 (en) 2001-11-15
NZ517605A (en) 2003-08-29
EP1210085A2 (en) 2002-06-05
PL354028A1 (en) 2003-12-15
IL148379A (en) 2006-12-10
EE200200129A (et) 2003-04-15
HK1049282A1 (en) 2003-05-09
EA200200348A1 (ru) 2002-08-29
AU7004400A (en) 2001-04-17
BG65827B1 (bg) 2010-02-26
AR025449A1 (es) 2002-11-27
CN1203855C (zh) 2005-06-01
US20040106617A1 (en) 2004-06-03
NO20021090D0 (no) 2002-03-05
DE60025627T2 (de) 2006-11-16
HK1049282B (zh) 2005-12-30
KR100869752B1 (ko) 2008-11-21
DE60025627D1 (de) 2006-04-06
HU228340B1 (en) 2013-03-28
FI109659B (fi) 2002-09-30
ATE315937T1 (de) 2006-02-15
FI19991925A (fi) 2001-03-10
EP1210085B1 (en) 2006-01-18
BG106589A (bg) 2002-11-29
HUP0202749A2 (hu) 2003-02-28
IL148379A0 (en) 2002-09-12
KR20020048400A (ko) 2002-06-22
ME00523B (me) 2011-10-10
RS50445B (sr) 2010-03-02
DK1210085T3 (da) 2006-05-08
AU771027B2 (en) 2004-03-11
TR200200620T2 (tr) 2002-09-23
MY125984A (en) 2006-09-29
HRP20020298B1 (en) 2007-02-28
US6730673B1 (en) 2004-05-04
ZA200201828B (en) 2003-08-27
IS2244B (is) 2007-05-15
BR0013924A (pt) 2002-05-21
CZ2002788A3 (cs) 2002-11-13
HUP0202749A3 (en) 2003-03-28
HRP20020298A2 (en) 2003-06-30
MXPA02002423A (es) 2002-08-12
SK287154B6 (sk) 2010-01-07
US6943164B2 (en) 2005-09-13
BR0013924B1 (pt) 2013-09-24
UA73954C2 (uk) 2005-10-17
WO2001019334A2 (en) 2001-03-22
JP2003509351A (ja) 2003-03-11
ES2256034T3 (es) 2006-07-16
TWI242434B (en) 2005-11-01

Similar Documents

Publication Publication Date Title
CO5180582A1 (es) Soluciones farmaceuticas de levosimendan
TR200302105T4 (tr) Siklosporin, hiyalüronik asit ve polisorbat içeren göz formülasyonları.
CU23367A3 (es) Formulación de moxifloxacino con sal común
AR024874A1 (es) Composiciones bactericidas
DE60118885D1 (de) Nitratsalze von antimikrobiellen wirkstoffen
HK1053603B (zh) 以促孕激素為主劑並含有抗壞血酸及/或抗壞血酸鹽的作皮膚敷用的藥物
CO5060481A1 (es) Suministro de agente activo aerosolizado modulado con resistencia de flujo
ATE282957T1 (de) Stabilisierte zusammensetzungen mit antibakterieller wirkung
BR9911319A (pt) microemulsão baseada em água de um piretróide
ES2171416T3 (es) Remedio contra la trombocitopenia.
MY130441A (en) Solutions containing epinastin
MXPA03011480A (es) Una preparacion farmaceutica acuosa de cilostazol para uso parenteral.
AR020455A1 (es) Composicion insecticida
AR032121A1 (es) Formulacion agroquimica.
HRP20010764B1 (en) Prucalopride oral solution
AR046634A1 (es) Una suspension fungicida acuosa concentrada
ATE344662T1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
AR020695A1 (es) Metodos para controlar macroinvertebrados en sistemas acuosos
WO2001067864A3 (en) Topical virucidal formulation
EP1591130A3 (en) Use of active solution for disinfecting and/or sterilizing a dental unit and method thereof
NZ508969A (en) Pesticidal emulsion containing levamisole in the aqueous phase and a macrocyclic lactone anthelmintic in the organic phase
BR0008442A (pt) Formulação efervescente farmacêutica, contendo metamizol
ES8704738A1 (es) Procedimiento para estabilizar y-0 aumentar el efecto microbicida de soluciones acuosas de h2o2
ES2190267T3 (es) Recipiente de plastico que contiene formulaciones de farmacos estabilizadas.
ECSP003603A (es) Formulacion de sal comun y moxifloxacina

Legal Events

Date Code Title Description
FG Application granted